The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma

Journal of Immunotherapy

Volumn 30, Issue 7, 2007, Pages 773-779

  Hernberg, Micaela ^a   Mattila, Petri S ^a   Rissanen, Marjo ^a   Hansson, Johan ^b   Aamdal, Steinar ^d   Bastholt, Lars ^e   Von Der Maase, Hans ^f   Schmidt, Henrik ^g   Stierner, Ulrika ^c   Tarkkanen, Jussi ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF OSLO   (Norway)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f Rigshospitalet

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adjuvant therapy; Helper cells; Immunotherapy; NK cells; Prognosis

Indexed keywords

ALPHA2B INTERFERON; CD69 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MONOCLONAL ANTIBODY CD56; MONOCLONAL ANTIBODY CD69; OKT 4; OKT 8; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CELL FUNCTION; CELL POPULATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MALE; MELANOMA; METASTASIS; MULTIVARIATE ANALYSIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERFERON ALFA-2B; LYMPHOCYTE SUBSETS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 34748907949     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31814e0898     Document Type: Article

References (29)

1. Balch CM, Buzaid AC, Soong SJ, et al. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol. 2003;21:43-52.
2. Balch CM, Soong SJ, Atkins MB, et al. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004;54:131-149; quiz 82-84.
3. Naruns PL, Nizze JA, Cochran AJ, et al. Recurrence potential of thin primary melanomas. Cancer. 1986;57:545-548.
4. Slingluff CL Jr, Vollmer RT, Reintgen DS, et al. Lethal "thin" malignant melanoma. Identifying patients at risk. Ann Surg. 1988;208:150-161.
5. Carlson JA, Slominski A, Linette GP, et al. Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging. Am J Clin Pathol. 2003;120(suppl):S101-S127.
6. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
7. Hernberg M, Muhonen T, Turunen JP, et al. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy. J Clin Oncol. 1996;14:1690-1696.
8. Hernberg MM, Hahka-Kemppinen MH, Pyrhonen SO. The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma. Melanoma Res. 2004;14:493-500.
9. Muhonen T, Hahka-Kemppinen M, Pakkala S, et al. Decreasing CD4/CD8 ratio during prolonged four-drug chemotherapy plus interferon treatment for metastatic melanoma. J Immunother. 1994;15:67-73.
10. Hakansson A, Gustafsson B, Krysander L, et al. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer. 1996;74:670-676.
11. Hakansson A, Gustafsson B, Krysander L, et al. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res. 1998;18:33-39.
12. Hakansson A, Gustafsson B, Krysander L, et al. Biochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes. Br J Cancer. 2001;85:1871-1877.
13. Hakansson A, Hakansson L, Gustafsson B, et al. On the effect of biochemotherapy in metastatic malignant melanoma: an immunopathological evaluation. Melanoma Res. 2003;13:401-407.
14. Markovic SN, Murasko DM. Role of natural killer and T-cells in interferon induced inhibition of spontaneous metastases of the B16F10L murine melanoma. Cancer Res. 1991;51:1124-1128.
15. Bakker AB, Phillips JH, Figdor CG, et al. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J Immunol. 1998;160:5239-5245.
16. Guillot B, Portales P, Thanh AD, et al. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment. Br J Dermatol. 2005;152:690-696.
17. Haanen JB, Baars A, Gomez R, et al. Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother. 2006;55:451-458. [Epub July 21, 2005].]
18. Jovic V, Konjevic G, Radulovic S, et al. Impaired perforin-dependent NK cell cytotoxicity and proliferative activity of peripheral blood T cells is associated with metastatic melanoma. Tumori. 2001;87:324-329.
19. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
20. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709-718.
21. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372-8377.
22. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005;23:741-750.
23. Brittenden J, Heys SD, Ross J, et al. Natural killer cells and cancer. Cancer. 1996;77:1226-1243.
24. Hansen BD, Schmidt H, von der Maase H, et al. Tumour-associated macrophages are related to progression in patients with metastatic melanoma following interleukin-2 based immunotherapy. Acta Oncol. 2006;45:400-405.
25. Hernberg M, Turunen JP, Muhonen T, et al. Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy. J Immunother. 1997;20:488-495.
26. Itoh K, Platsoucas CD, Balch CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med. 1988;168:1419-1441.
27. Rubin JT, Elwood LJ, Rosenberg SA, et al. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res. 1989;49:7086-7092.
28. Schneeberger A, Koszik F, Stingl G. Immunologic host defense in melanoma: delineation of effector mechanisms involved and of strategies for the augmentation of their efficacy. J Invest Dermatol. 1995;105:110S-116S.
29. Chen S, Kawashima H, Lowe JB, et al. Suppression of tumor formation in lymph nodes by L-selectin-mediated natural killer cell recruitment. J Exp Med. 2005;202:1679-1689.